Theralase® Announces Warrant Extension
29 sept. 2022 17h01 HE
|
Theralase Technologies Inc.
TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and...
Theralase® Closes $2.5M Private Placement Equity Financing
22 sept. 2022 17h55 HE
|
Theralase Technologies Inc.
TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase Releases Q222 Interim Financial Statements
29 août 2022 19h45 HE
|
Theralase Technologies Inc.
TORONTO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase Expands Intellectual Property Portfolio
28 juin 2022 07h00 HE
|
Theralase Technologies Inc.
TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase® Research - One of the Top 10 Most Downloaded Papers
24 juin 2022 07h00 HE
|
Theralase Technologies Inc.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Phase Ib NMIBC Clinical Study Published
21 juin 2022 07h00 HE
|
Theralase Technologies Inc.
TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase Releases Q122 Interim Financial Statements
30 mai 2022 17h53 HE
|
Theralase Technologies Inc.
TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase Release FY2021 Audited Financial Statements
29 avr. 2022 21h11 HE
|
Theralase Technologies Inc.
TORONTO, April 29, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
05 avr. 2022 07h00 HE
|
Theralase Technologies Inc.
TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine
07 févr. 2022 07h00 HE
|
Theralase Technologies Inc.
TORONTO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...